On June 2, Ge Longhui Pharmaceutical (688192.SH) issued an announcement. Recently, at the 2024 American Society of Clinical Oncology (ASCO) conference, Digger (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) released the self-developed novel Class I lung cancer target drug Schwarzhe for the first time in the form of an oral report(Generic name: Suvortinib tablets) Preliminary analysis results of the first international multi-center registered clinical study “Goku 1B” (WU-KONG1 Part B, WU-KONG1B) for the treated epidermal growth factor receptor (EGFR) exon 20 mutation (exon20Ins) non-small cell lung cancer (NSCLC). The study reached the main end.Highly efficient and low in toxicity, showing the best potential of its kind in the world.
迪哲医药(688192.SH)：舒沃哲首个全球注册临床研究达到主要研究终点并在2024年美国临床肿瘤学会(ASCO)大会口头报告
Digger Pharmaceuticals (688192.SH): Schwarzer's first globally registered clinical study reached a major research endpoint and gave an oral report at the 2024 American Society of Clinical Oncology (ASCO) Conference
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.